Navigation Links
Feed a cold -- starve a tumor
Date:10/20/2011

The condition tuberous sclerosis, due to mutation in one of two tumor suppressor genes, TSC1 or TSC2, causes the growth of non-malignant tumors throughout the body and skin. These tumors can be unsightly and cause serious damage to organs. Growth of tumors in the brain may cause seizures and in the kidney, liver or heart, tumors can disrupt normal function, to the extent of causing the organ to fail. New research published in BioMed Central's open access journal Cell and Bioscience shows that the growth of glucose-dependent TSC-related tumors can be restricted by 2-deoxyglucose, which blocks glucose metabolism, but not by restricting dietary carbohydrates.

TSC1 and TSC2 normally inhibit the mTOR signaling pathway but if the TSC genes are mutated, so that they no longer function, unregulated mTORC1 drives glycolysis and cell growth. Rapamycin works by blocking mTORC1 and is currently used to treat tuberous sclerosis. However, rapamycin is an immunosuppressant and can have significant side effects, especially when used long term. A group of researchers from the University of Washington, led by Prof Yeung, looked in detail at the potential of blocking cell proliferation by directly reducing glycolysis.

Surprisingly TSC2-negative tumors in mice kept on an unrestricted carbohydrate-free diet grew bigger than those on a western-style diet. However the glucose analogue, 2-deoxyglucose (2DG), which disrupts glucose metabolism, reduced the tumor size in mice on either diet. Prof Yeung explained, "Treatment with 2DG significantly reduced the rate at which the tumor cells divided, especially when paired with a diet which contained carbohydrates. This combination of 2DG and a western-style diet imposed the greatest energy stress on the tumors and correlated with the lowest levels of serum glucose. On the other hand, while the carbohydrate-free (and high-fat) diet provided enough free fatty acids to sustain tumor growth, some of the saturated fatty acids appeared toxic to the tumor cells. This in turn led to an accumulation of liquefied, necrotic materials that contributed to greater tumor size."

Compounds such as 2DG are able to inhibit TSC2-negative tumor growth by restricting glycolysis in a manner not seen by reducing dietary glucose. 2DG is currently undergoing trials for use in prostate cancer. This and other metabolic interventions hold promise for future cancer treatment.


'/>"/>

Contact: Dr. Hilary Glover
hilary.glover@biomedcentral.com
44-203-192-2370
BioMed Central
Source:Eurekalert

Related medicine news :

1. Research aims to starve breast cancer cells
2. A double block of blood vessels to starve cancerous tumors
3. A new cancer vaccine starves tumors of blood
4. More evidence that allergies may help in fighting brain tumors
5. Hispanic women have higher incidence of rare breast tumor
6. John Theurer Cancer Center hosts New Frontiers in the Management of Solid and Liquid Tumors
7. Bone marrow cells migrate to tumors and can slow their growth
8. Dioxin-like chemical messenger makes brain tumors more aggressive
9. Grant to LSUHSC Tumor Registry creates pediatric cancer research tool
10. Knockout of protein prevents colon tumor formation in mice
11. New technique identifies first events in tumor development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: